[1] 俞海英, 丁巧云, 郭银燕, 等. 核苷类药物治疗慢性乙型肝炎10年51例随访. 肝脏, 2017, 22:523-525.
[2] Vourli G, Papatheodoridis G, Raptopoulou M, et al. Association of antiviral therapy with reduced disease progression in chronic hepatitis B patients: Results from a nation-wide cohort study. Hippokratia, 2016, 20:214-221.
[3] 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2010年版). 肝脏, 2011, 3:66-82.
[4] Chon YE, Park JY, Myoung SM, et al. Improvement of liver fibrosis after long-term antiviral therapy assessed by fibroscan in chronic hepatitis B patients with advanced fibrosis. Am J Gastroenterol, 2017, 112:882-891.
[5] 刘璐璐, 任艺, 何毅怀,等. 慢性乙型肝炎合并非酒精性脂肪性肝病的研究进展. 临床肝胆病杂志, 2017, 33:538-542.
[6] 刘琪, 张之伦. 双环醇用于慢性乙型肝炎联合治疗研究进展. 中国慢性病预防与控制, 2016, 24:152-155.
[7] 李娟, 张欢欢. 双环醇联合抗病毒治疗对孕中期慢性乙型肝炎患者肝功能、病毒复制及母婴传播的影响. 广西医学, 2017, 39:1362-1363.
[8] 王爱华, 冯欣. 双环醇片联合核苷(酸)类似物治疗慢性乙型肝炎疗效和安全性Meta分析. 胃肠病学和肝病学杂志, 2016, 25:652-657.
[9] Shim JJ, Oh CH, Kim JW, et al. Liver cirrhosis stages and the incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving antiviral therapy. Scand J Gastroentero, 2017, 52:1029-1036. |
